Penas-Prado, M., Yuan, Y., Wall, K., Vera, E., Ikiddeh-Barnes, U., Blackburn, K., Chambers, C., Ratnam, N., Frederico, S., Acquaye, A., Aldape, K., Briceno, N., Choi, A., Christ, A., Jammula, V., Leeper, H., Levine, J., Lindsley, M., Reyes, J., Roche, K., Rogers, J., Timmer, M., Boris, L., Burton, E., Lollo, N., Panzer, M., Polskin, L., Pillai, V., Quezado, M., Theeler, B., Wu, J., Armstrong, T., & Gilbert, M. (2021). cTIM-32. IMMUNE CHECKPOINT INHIBITOR NIVOLUMAB IN PEOPLE WITH RECURRENT SELECT RARE CNS CANCERS: RESULTS OF INTERIM ANALYSIS IN A HEAVILY PRETREATED COHORT. Neuro-oncology, 23, vi57–vi58. http://access.bl.uk/ark:/81055/vdc_100146090749.0x00002f